drugset / Trial / NCT05307198
Rectal Artery Infusion Chemotherapy Combined With Anti-PD1 Antibody for MSS LARC
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to explore whether rectal artery infusion chemotherapy combined with anti-PD1 antibody is an effective neoadjuvant therapy for the microsatellite stable locally advanced rectal cancer.
Timeline
- Start
- 2022-05-11
- Primary completion
- 2024-04-25
- Completion
- 2025-04-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Capecitabine | Small molecule | 1000 mg/m2 | Oral |
| Subject | Oxaliplatin | Small molecule | 85 mg/m2 | Intravenous |
| Subject | Sintilimab | Monoclonal antibody | 200 mg/m2 | — |